BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27536184)

  • 1. Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia.
    Sibai H; Seki JT; Wang TQ; Sakurai N; Atenafu EG; Yee KW; Schuh AC; Gupta V; Minden MD; Schimmer AD; Brandwein JM
    Curr Oncol; 2016 Aug; 23(4):e355-61. PubMed ID: 27536184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
    Sibai H; Chen R; Liu X; Falcone U; Schimmer A; Schuh A; Law A; McNamara C; Maze D; Yee K; Minden M; Chan SM; Gupta V; Murphy T; Sakurai N; Atenafu EG; Brandwein JM; Seki JT
    Br J Haematol; 2020 Dec; 191(5):748-754. PubMed ID: 32395867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
    Chen R; Liu X; Law AD; Kanfar S; Maze D; Chan SM; Gupta V; Yee KW; Minden MD; Schimmer AD; Schuh AC; McNamara CJ; Murphy T; Xu A; Falcone U; Seki J; Sibai H
    Curr Oncol; 2020 Dec; 28(1):128-137. PubMed ID: 33704181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
    Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
    Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.
    Grace RF; DeAngelo DJ; Stevenson KE; Neuberg D; Sallan SE; Mourad YRA; Bergeron J; Seftel MD; Kokulis C; Connors JM
    J Thromb Thrombolysis; 2018 Feb; 45(2):306-314. PubMed ID: 29260426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin versus tinzaparin for venous thromboembolic prophylaxis during rehabilitation after acute spinal cord injury: a retrospective cohort study comparing safety and efficacy.
    Marciniak CM; Kaplan J; Welty L; Chen D
    PM R; 2012 Jan; 4(1):11-7. PubMed ID: 22269449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and safety of delivering full-dose anticoagulation therapy in children treated according to Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium therapy protocols.
    Bhatt MD; Parmar N; Fowler JA; Chan AKC; Athale UH
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27483. PubMed ID: 30362248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study.
    Athale UH; Laverdiere C; Nayiager T; Delva YL; Foster G; Thabane L; Chan AK
    BMC Cancer; 2017 May; 17(1):313. PubMed ID: 28472942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
    Chen R; Atenafu EG; Seki J; Liu X; Chan S; Gupta V; Maze D; Shuh AC; Minden MD; Yee K; Schimmer AD; Sibai H
    Br J Haematol; 2023 May; 201(4):645-652. PubMed ID: 36794878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.
    Bickford A; Majercik S; Bledsoe J; Smith K; Johnston R; Dickerson J; White T
    Am J Surg; 2013 Dec; 206(6):847-51, discussion 851-2. PubMed ID: 24070664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.
    Dudley RR; Aziz I; Bonnici A; Saluja RS; Lamoureux J; Kalmovitch B; Gursahaney A; Razek T; Maleki M; Marcoux J
    J Neurotrauma; 2010 Dec; 27(12):2165-72. PubMed ID: 20939698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.
    Elhasid R; Lanir N; Sharon R; Weyl Ben Arush M; Levin C; Postovsky S; Ben Barak A; Brenner B
    Blood Coagul Fibrinolysis; 2001 Jul; 12(5):367-70. PubMed ID: 11505079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
    Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
    Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH; Lensing AW; Brighton TA; Lyons RM; Rehm J; Trajanovic M; Davidson BL; Beyer-Westendorf J; Pap ÁF; Berkowitz SD; Cohen AT; Kovacs MJ; Wells PS; Prandoni P
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study.
    Mitchell L; Lambers M; Flege S; Kenet G; Li-Thiao-Te V; Holzhauer S; Bidlingmaier C; Frühwald MC; Heller C; Schmidt W; Pautard B; Nowak-Göttl U
    Blood; 2010 Jun; 115(24):4999-5004. PubMed ID: 20339086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of venous thromboembolism in the rehabilitation phase after spinal cord injury: prophylaxis with low-dose heparin or enoxaparin.
    Spinal Cord Injury Thromboprophylaxis Investigators
    J Trauma; 2003 Jun; 54(6):1111-5. PubMed ID: 12813331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.